

**Epidemiology Note**

## Cancer Incidence and Incidence Rates in Japan in 2005: Based on Data from 12 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project

Tomohiro Matsuda<sup>1,\*</sup>, Tomomi Marugame<sup>1</sup>, Ken-ichi Kamo<sup>2</sup>, Kota Katanoda<sup>1</sup>, Wakiko Ajiki<sup>1</sup> and Tomotaka Sobue<sup>1</sup> The Japan Cancer Surveillance Research Group

<sup>1</sup>Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo and <sup>2</sup>Division of Mathematics, School of Medicine, Liberal Arts and Sciences, Sapporo Medical University, Sapporo, Hokkaido, Japan

\*For reprints and all correspondence: Tomohiro Matsuda, Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: tomatsud@ncc.go.jp

Received July 20, 2010; accepted August 2, 2010

The Japan Cancer Surveillance Research Group estimated the cancer incidence in 2005 as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project, on the basis of data collected from 12 of 30 population-based cancer registries. The total number of incidences in Japan for 2005 was estimated as 646 802 (C00–C96). The leading cancer site was the stomach for men and the breast for women. Age-standardized incidence rates remained almost the same level as the previous 2 years.

*Key words:* cancer incidence – incidence estimates – cancer registry – Japan

The Japan Cancer Surveillance Research Group is involved in cancer monitoring in Japan since 2000 (1–5). This group estimated the cancer incidence in 2005 as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project, on the basis of data collected from 12 of 30 population-based cancer registries: Miyagi, Yamagata, Chiba, Kanagawa, Niigata, Fukui, Shiga, Tottori, Okayama, Hiroshima, Nagasaki and Kumamoto. If data from all 30 registries were used, this would have led to a large underestimation of national cancer incidence because of under-registration. The methods of registry selection, estimation of incidence and the limitations of these methods have been explained in previous studies (6–8). We maintained the same methodology since the MCIJ2003: (i) we invited all 30 population-based cancer registries in Japan to participate, and from these, we selected the 12 cancer registries with high-quality data in order to estimate the national incidence, and (ii) we used 2005 data alone for the national estimation. For this year, data from Osaka and Saga prefectures, regularly considered as one of the registries with high quality, were not available for the MCIJ project. The other registries remained since the previous estimation in 2004.

The number of incidences, crude rates, age-standardized rates and quality indicators of registration in 2005 are shown in Table 1, and the age-specific number of incidences and the rates according to sex and primary site are shown in Tables 2 and 3. The total number of incidences in Japan for 2005 was estimated as 646 802 (C00–C96). The time trends of age-standardized incidence rates for the five major sites and male- and female-specific sites in 1975–2005 are shown in Fig. 1 (standard population: the world population) and in Fig. 2 (standard population: the 1985 Japanese model population). The leading cancer site according to the crude and age-standardized incidence rates was the stomach for men and the breast for women since the research group took over national estimation of incidence, as shown in Figs 1 and 2. Age-standardized incidence rates remained almost the same level as the previous 2 years. It is thought to be partly due to that the development of hospital-based cancer registry in designated cancer care hospitals was calmed down in 2005. The estimated cancer incidence data in Japan by sex, site, 5-year age group and calendar year during the period 1975–2005 are available as a booklet and as an electronic database

**Table 1.** Incidence, completeness of reporting and accuracy of diagnosis in Japan according to sex and primary site, 2005

Primary sites	ICD-10th	Number of incidence	Crude rate <sup>a</sup>	Age-standardized rate <sup>a</sup>		Completeness of reporting		Accuracy of diagnosis
				World population	Japanese 1985 model population	DCO/I (%)	I/M	MV/I (%)
Male								
All sites (incl. CIS)	C00–C96, D00–D09	390 835	626.9	288.5	408.4	14.9	1.99	74.8
All sites	C00–C96	379 436	608.6	279.7	396.1	15.2	1.93	74.3
Lip, oral cavity and pharynx	C00–C14	7417	11.9	6.0	8.2	12.8	1.79	80.6
Esophagus	C15	14 818	23.8	11.1	15.5	13.1	1.57	80.0
Stomach	C16	80 102	128.5	59.3	83.9	12.1	2.45	84.0
Colon	C18	37 126	59.5	27.1	38.7	10.3	2.76	84.1
Rectum	C19–C20	22 344	35.8	17.5	24.2	10.3	2.57	85.3
Colon and rectum	C18–C20	59 470	95.4	44.6	62.9	10.3	2.69	84.6
Liver	C22	28 729	46.1	21.4	30.1	23.5	1.24	31.3
Gallbladder etc.	C23–C24	9237	14.8	6.1	9.1	25.3	1.18	48.8
Pancreas	C25	13 108	21.0	9.5	13.5	26.5	1.07	35.9
Larynx	C32	3903	6.3	2.9	4.0	6.1	3.88	89.3
Trachea, bronchus and lung	C33–C34	58 264	93.4	39.4	58.5	21.7	1.29	68.8
Melanoma of skin etc.	C43–C44	4798	7.7	3.5	5.0	4.2	7.64	92.5
Prostate	C61	42 997	69.0	28.2	42.0	10.3	4.64	83.5
Bladder	C67	12 619	20.2	8.8	12.9	10.3	3.05	83.2
Kidney, renal pelvis, ureter etc.	C64–C66, C68	9758	15.7	7.7	10.6	13.2	2.43	76.1
Brain and nervous system	C70–C72	2496	4.0	2.8	3.3	25.3	2.71	68.2
Thyroid	C73	2126	3.4	2.0	2.6	4.5	4.77	91.0
Malignant lymphoma	C81–C85, C96	9667	15.5	8.0	10.9	12.4	1.99	86.1
Multiple myeloma	C88, C90	2242	3.6	1.5	2.3	23.2	1.14	67.4
All leukaemias	C91–C95	5200	8.3	5.3	6.3	21.6	1.21	85.9

## Female

All sites (incl. CIS)	C00–C96, D00–D09	285 240	436.0	202.6	271.1	15.0	2.21	74.9
All sites	C00–C96	267 366	408.7	183.8	247.7	15.8	2.07	73.7
Lip, oral cavity and pharynx	C00–C14	3498	5.3	2.3	3.1	14.6	2.29	80.4
Esophagus	C15	2678	4.1	1.5	2.1	20.9	1.56	71.6
Stomach	C16	37 035	56.6	21.8	30.7	15.6	2.10	80.2
Colon	C18	31 069	47.5	17.9	25.1	14.3	2.27	79.5
Rectum	C19–C20	13 517	20.7	8.9	12.1	11.0	2.70	83.8
Colon and rectum	C18–C20	44 586	68.2	26.8	37.2	13.3	2.39	80.7
Liver	C22	13 465	20.6	6.9	10.1	27.6	1.22	26.7
Gallbladder etc.	C23–C24	9399	14.4	4.0	6.1	30.9	1.08	38.4
Pancreas	C25	11 691	17.9	5.8	8.4	28.8	1.10	30.7
Larynx	C32	214	0.3	0.1	0.2	16.2	2.55	73.7
Trachea, bronchus and lung	C33–C34	25 617	39.2	14.3	20.2	23.3	1.52	68.0
Melanoma of skin etc.	C43–C44	4342	6.6	2.3	3.2	8.2	7.50	90.1
Breast (incl. CIS)	C50, D05	50 695	77.5	47.5	61.4	5.0	4.73	90.4
Breast (only invasive)	C50	47 583	72.7	44.4	57.4	5.3	4.44	89.9
Uterus (incl. CIS)	C53–C55, D06	25 424	38.9	27.5	34.3	5.5	4.73	89.9
Uterus (only invasive)	C53–C55	17 476	26.7	16.4	21.1	7.4	3.25	87.2
Cervix uteri	C53	8474	13.0	8.7	11.0	6.1	3.44	88.6
Corpus uteri	C54	8189	12.5	7.3	9.5	3.2	5.61	92.1
Ovary	C56	8304	12.7	7.4	9.4	13.4	1.86	77.7
Bladder	C67	3858	5.9	1.8	2.7	19.8	2.04	71.7
Kidney, renal pelvis, ureter etc.	C64–C66, C68	4884	7.5	3.1	4.2	16.8	2.31	71.4
Brain and nervous system	C70–C72	2567	3.9	2.3	2.7	28.2	3.49	64.6
Thyroid	C73	7093	10.8	6.7	8.5	7.5	6.93	88.5
Malignant lymphoma	C81–85 C96	7324	11.2	5.0	6.6	13.7	1.97	83.7
Multiple myeloma	C88 C90	2171	3.3	1.2	1.7	26.3	1.13	66.8
All leukaemias	C91–C95	3832	5.9	3.4	4.0	22.6	1.29	83.5

ICD-10th, International Classification of Disease, 10th Revision; DCO/I, proportion of cases with the death certificate only to incident cases; I/M, number of incidence/number of deaths; MV/I, proportion of microscopically verified cases to incident cases; CIS, carcinoma *in situ*.

<sup>a</sup>Per 100 000 population.

**Table 2.** Age-specific incidence in Japan according to sex and primary site, 2005

Primary sites	ICD-10th	Age group (years)																	
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
Male																			
All sites (incl. CIS)	C00-C96, D00-D09	411	251	264	325	694	915	1592	2633	4640	7543	17 618	34 039	47 157	60 310	73 404	69 067	40 247	29 725
All sites	C00-C96	411	247	264	320	694	895	1577	2540	4422	7221	16 847	32 892	45 627	58 269	71 267	67 254	39 392	29 297
Lip, oral cavity and pharynx	C00-C14	1	7	14	2	36	39	58	71	123	261	543	1125	1157	1040	1060	1054	494	332
Esophagus	C15	0	2	0	0	0	0	0	22	61	304	717	1779	2364	2846	2604	2304	1196	619
Stomach	C16	4	0	0	6	46	66	168	435	1060	1708	4174	7786	10 330	12 802	14 933	13 373	7552	5659
Colon	C18	0	0	0	6	1	62	115	311	456	658	1786	3257	4635	5947	6828	6253	3979	2832
Rectum	C19-C20	0	0	0	5	4	20	120	171	406	734	1437	2830	3320	3508	3825	3184	1640	1140
Colon and rectum	C18-C20	0	0	0	11	5	82	235	482	862	1392	3223	6087	7955	9455	10 653	9437	5619	3972
Liver	C22	15	0	0	0	6	22	56	160	271	501	1523	2795	4111	4824	5840	4716	2448	1441
Gallbladder etc.	C23-C24	0	0	0	0	11	1	0	41	24	77	282	481	877	1241	1541	1908	1481	1272
Pancreas	C25	0	0	1	0	0	10	7	59	114	181	698	1216	1625	2214	2301	2049	1503	1130
Larynx	C32	0	0	0	0	0	0	0	12	23	28	160	454	723	690	550	721	343	199
Trachea, bronchus and lung	C33-C34	0	0	5	0	0	46	71	205	388	802	1889	4084	6049	7396	11 080	12 646	7755	5848
Melanoma of skin etc.	C43-C44	0	0	1	6	8	16	28	83	103	75	169	330	338	737	866	701	602	735
Prostate	C61	0	0	0	0	0	0	8	0	7	66	487	1844	4333	7797	10 615	9458	4869	3513
Bladder	C67	5	0	0	0	0	10	46	49	188	254	402	1051	1286	1506	2280	2461	1687	1394
Kidney, renal pelvis, ureter etc.	C64-C66 C68	16	23	0	0	1	23	29	85	262	306	649	1149	984	1565	1903	1462	765	536
Brain and nervous system	C70-C72	31	44	89	48	129	63	85	59	114	100	126	194	269	293	285	294	178	95
Thyroid	C73	0	0	0	18	36	58	81	105	65	123	215	361	247	245	221	217	106	28
Malignant lymphoma	C81-85 C96	9	43	22	77	48	69	141	228	264	381	597	674	1046	1302	1604	1521	892	749
Multiple myeloma	C88 C90	0	0	0	0	3	0	2	5	5	44	75	160	239	270	478	421	297	243
All leukaemias	C91-C95	162	84	48	64	112	82	156	149	117	164	275	365	439	671	777	750	478	307

Female																			
All sites (incl. CIS)	C00–C96 D00–D09	248	178	209	298	972	2407	4945	6920	10 446	14 101	18 686	26 896	28 609	30 500	35 638	36 211	31 284	36 692
All sites	C00–C96	248	178	209	285	596	1372	3149	5140	8819	12 773	17 301	25 607	27 125	29 124	34 121	34 887	30 392	36 040
Lip, oral cavity and pharynx	C00–C14	0	2	14	4	21	28	80	30	53	144	124	280	362	440	520	508	346	542
Esophagus	C15	0	0	0	0	0	0	4	2	10	81	147	258	279	328	329	378	395	467
Stomach	C16	0	0	0	4	0	41	281	399	781	1087	1644	2922	3333	4238	5397	5993	5080	5835
Colon	C18	0	0	17	0	7	25	117	173	356	703	1560	2313	3030	4278	4351	4720	4273	5146
Rectum	C19–C20	0	0	0	0	0	6	63	189	324	474	926	1361	1635	1773	1764	1761	1408	1833
Colon and rectum	C18–C20	0	0	17	0	7	31	180	362	680	1177	2486	3674	4665	6051	6115	6481	5681	6979
Liver	C22	23	0	0	0	4	5	30	18	81	62	250	707	1122	1806	2569	2787	2060	1941
Gallbladder etc.	C23–C24	0	0	0	0	5	0	6	24	30	68	209	262	512	801	1265	1553	1987	2677
Pancreas	C25	0	0	0	0	2	8	12	20	73	160	295	762	891	1171	1734	2006	1873	2684
Larynx	C32	0	0	0	0	0	0	0	0	7	14	4	14	31	11	23	10	43	57
Trachea, bronchus and lung	C33–C34	0	0	0	0	0	47	93	73	261	449	978	2186	2686	3021	3871	4159	3418	4375
Melanoma of skin etc.	C43–C44	0	0	17	7	26	17	71	22	81	99	91	193	290	303	492	689	755	1189
Breast (incl. CIS)	C50 D05	0	0	0	7	19	159	805	2092	4374	6139	6244	7245	6667	4930	4573	3352	2336	1753
Breast (only invasive)	C50	0	0	0	7	19	146	761	1973	4038	5732	5751	6903	6246	4629	4275	3179	2218	1706
Uterus (incl. CIS)	C53–C55 D06	0	0	6	28	413	1397	2412	2697	2455	2156	2446	3031	2157	1566	1589	1338	836	897
Uterus (only invasive)	C53–C55	0	0	6	19	64	402	726	1142	1309	1439	1966	2676	1915	1378	1464	1286	804	880
Cervix uteri	C53	0	0	0	19	50	334	553	908	920	704	857	1018	566	562	625	590	357	411
Corpus uteri	C54	0	0	6	0	14	67	171	226	361	709	1088	1579	1298	764	797	585	313	211
Ovary	C56	0	11	22	45	111	166	203	289	348	663	969	1186	985	805	757	629	513	602
Bladder	C67	0	0	0	0	0	13	9	23	17	55	143	156	242	293	553	621	748	985
Kidney, renal pelvis, ureter etc.	C64–C66 C68	15	35	2	10	9	29	17	32	83	93	281	433	474	521	812	725	662	651
Brain and nervous system	C70–C72	46	32	51	17	28	21	88	56	76	96	191	177	258	317	258	247	279	329
Thyroid	C73	0	0	4	22	110	200	279	313	451	626	672	935	857	767	663	522	361	311
Malignant lymphoma	C81–85 C96	5	14	14	84	32	125	58	94	158	217	382	724	676	812	1076	981	895	977
Multiple myeloma	C88 C90	0	0	0	0	0	0	0	4	13	55	44	183	224	269	330	293	400	356
All leukaemias	C91–C95	60	66	37	35	58	47	174	77	93	180	196	343	388	387	393	498	388	412

**Table 3.** Age-specific incidence rate per 100 000 population in Japan according to sex and primary site, 2005

Primary sites	ICD-10th	Age group (years)																	
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
Male																			
All sites (incl. CIS)	C00-C96, D00-D09	14.4	8.3	8.6	9.6	18.5	21.8	32.3	59.8	114.1	195.0	401.9	670.4	1135.1	1701.3	2414.8	3061.1	3291.8	3665.7
All sites	C00-C96	14.4	8.1	8.6	9.5	18.5	21.3	32.0	57.7	108.8	186.7	384.4	647.8	1098.2	1643.7	2344.5	2980.7	3221.9	3612.9
Lip, oral cavity and pharynx	C00-C14	0.0	0.2	0.5	0.1	1.0	0.9	1.2	1.6	3.0	6.7	12.4	22.2	27.8	29.3	34.9	46.7	40.4	40.9
Esophagus	C15	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	1.5	7.9	16.4	35.0	56.9	80.3	85.7	102.1	97.8	76.3
Stomach	C16	0.1	0.0	0.0	0.2	1.2	1.6	3.4	9.9	26.1	44.2	95.2	153.3	248.6	361.1	491.3	592.7	617.7	697.9
Colon	C18	0.0	0.0	0.0	0.2	0.0	1.5	2.3	7.1	11.2	17.0	40.7	64.1	111.6	167.8	224.6	277.1	325.4	349.2
Rectum	C19-C20	0.0	0.0	0.0	0.1	0.1	0.5	2.4	3.9	10.0	19.0	32.8	55.7	79.9	99.0	125.8	141.1	134.1	140.6
Colon and rectum	C18-C20	0.0	0.0	0.0	0.3	0.1	2.0	4.8	10.9	21.2	36.0	73.5	119.9	191.5	266.7	350.5	418.2	459.6	489.8
Liver	C22	0.5	0.0	0.0	0.0	0.2	0.5	1.1	3.6	6.7	13.0	34.7	55.0	99.0	136.1	192.1	209.0	200.2	177.7
Gallbladder etc.	C23-C24	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.9	0.6	2.0	6.4	9.5	21.1	35.0	50.7	84.6	121.1	156.9
Pancreas	C25	0.0	0.0	0.0	0.0	0.0	0.2	0.1	1.3	2.8	4.7	15.9	23.9	39.1	62.5	75.7	90.8	122.9	139.4
Larynx	C32	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.7	3.7	8.9	17.4	19.5	18.1	32.0	28.1	24.5
Trachea, bronchus and lung	C33-C34	0.0	0.0	0.2	0.0	0.0	1.1	1.4	4.7	9.5	20.7	43.1	80.4	145.6	208.6	364.5	560.5	634.3	721.2
Melanoma of skin etc.	C43-C44	0.0	0.0	0.0	0.2	0.2	0.4	0.6	1.9	2.5	1.9	3.9	6.5	8.1	20.8	28.5	31.1	49.2	90.6
Prostate	C61	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	1.7	11.1	36.3	104.3	219.9	349.2	419.2	398.2	433.2
Bladder	C67	0.2	0.0	0.0	0.0	0.0	0.2	0.9	1.1	4.6	6.6	9.2	20.7	31.0	42.5	75.0	109.1	138.0	171.9
Kidney, renal pelvis, ureter etc.	C64-C66, C68	0.6	0.8	0.0	0.0	0.0	0.5	0.6	1.9	6.4	7.9	14.8	22.6	23.7	44.1	62.6	64.8	62.6	66.1
Brain and nervous system	C70-C72	1.1	1.4	2.9	1.4	3.4	1.5	1.7	1.3	2.8	2.6	2.9	3.8	6.5	8.3	9.4	13.0	14.6	11.7
Thyroid	C73	0.0	0.0	0.0	0.5	1.0	1.4	1.6	2.4	1.6	3.2	4.9	7.1	5.9	6.9	7.3	9.6	8.7	3.5
Malignant lymphoma	C81-85, C96	0.3	1.4	0.7	2.3	1.3	1.6	2.9	5.2	6.5	9.9	13.6	13.3	25.2	36.7	52.8	67.4	73.0	92.4
Multiple myeloma	C88, C90	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	1.1	1.7	3.2	5.8	7.6	15.7	18.7	24.3	30.0
All leukaemias	C91-C95	5.7	2.8	1.6	1.9	3.0	2.0	3.2	3.4	2.9	4.2	6.3	7.2	10.6	18.9	25.6	33.2	39.1	37.9

Female																				
All sites (incl. CIS)	C00–C96, D00–D09	9.1	6.2	7.1	9.3	27.0	59.0	102.6	159.7	260.2	365.5	423.4	519.4	651.7	784.5	990.6	1204.4	1428.7	1734.2	
All sites	C00–C96	9.1	6.2	7.1	8.9	16.6	33.6	65.3	118.6	219.6	331.0	392.0	494.6	617.9	749.2	948.4	1160.4	1387.9	1703.4	
Lip, oral cavity and pharynx	C00–C14	0.0	0.1	0.5	0.1	0.6	0.7	1.7	0.7	1.3	3.7	2.8	5.4	8.2	11.3	14.5	16.9	15.8	25.6	
Esophagus	C15	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	2.1	3.3	5.0	6.4	8.4	9.1	12.6	18.0	22.1	
Stomach	C16	0.0	0.0	0.0	0.1	0.0	1.0	5.8	9.2	19.5	28.2	37.3	56.4	75.9	109.0	150.0	199.3	232.0	275.8	
Colon	C18	0.0	0.0	0.6	0.0	0.2	0.6	2.4	4.0	8.9	18.2	35.3	44.7	69.0	110.0	120.9	157.0	195.1	243.2	
Rectum	C19–C20	0.0	0.0	0.0	0.0	0.0	0.1	1.3	4.4	8.1	12.3	21.0	26.3	37.2	45.6	49.0	58.6	64.3	86.6	
Colon and rectum	C18–C20	0.0	0.0	0.6	0.0	0.2	0.8	3.7	8.4	16.9	30.5	56.3	71.0	106.3	155.6	170.0	215.6	259.4	329.9	
Liver	C22	0.8	0.0	0.0	0.0	0.1	0.1	0.6	0.4	2.0	1.6	5.7	13.7	25.6	46.5	71.4	92.7	94.1	91.7	
Gallbladder etc.	C23–C24	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.6	0.7	1.8	4.7	5.1	11.7	20.6	35.2	51.7	90.7	126.5	
Pancreas	C25	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.5	1.8	4.1	6.7	14.7	20.3	30.1	48.2	66.7	85.5	126.9	
Larynx	C32	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.1	0.3	0.7	0.3	0.6	0.3	2.0	2.7	
Trachea, bronchus and lung	C33–C34	0.0	0.0	0.0	0.0	0.0	1.2	1.9	1.7	6.5	11.6	22.2	42.2	61.2	77.7	107.6	138.3	156.1	206.8	
Melanoma of skin etc.	C43–C44	0.0	0.0	0.6	0.2	0.7	0.4	1.5	0.5	2.0	2.6	2.1	3.7	6.6	7.8	13.7	22.9	34.5	56.2	
Breast (incl. CIS)	C50, D05	0.0	0.0	0.0	0.2	0.5	3.9	16.7	48.3	108.9	159.1	141.5	139.9	151.9	126.8	127.1	111.5	106.7	82.9	
Breast (only invasive)	C50	0.0	0.0	0.0	0.2	0.5	3.6	15.8	45.5	100.6	148.6	130.3	133.3	142.3	119.1	118.8	105.7	101.3	80.6	
Uterus (incl. CIS)	C53–C55, D06	0.0	0.0	0.2	0.9	11.5	34.2	50.0	62.2	61.1	55.9	55.4	58.5	49.1	40.3	44.2	44.5	38.2	42.4	
Uterus (only invasive)	C53–C55	0.0	0.0	0.2	0.6	1.8	9.8	15.1	26.4	32.6	37.3	44.5	51.7	43.6	35.4	40.7	42.8	36.7	41.6	
Cervix uteri	C53	0.0	0.0	0.0	0.6	1.4	8.2	11.5	21.0	22.9	18.2	19.4	19.7	12.9	14.5	17.4	19.6	16.3	19.4	
Corpus uteri	C54	0.0	0.0	0.2	0.0	0.4	1.6	3.5	5.2	9.0	18.4	24.7	30.5	29.6	19.7	22.2	19.5	14.3	10.0	
Ovary	C56	0.0	0.4	0.7	1.4	3.1	4.1	4.2	6.7	8.7	17.2	22.0	22.9	22.4	20.7	21.0	20.9	23.4	28.5	
Bladder	C67	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.5	0.4	1.4	3.2	3.0	5.5	7.5	15.4	20.7	34.2	46.6	
Kidney, renal pelvis, ureter etc.	C64–C66, C68	0.6	1.2	0.1	0.3	0.3	0.7	0.4	0.7	2.1	2.4	6.4	8.4	10.8	13.4	22.6	24.1	30.2	30.8	
Brain and nervous system	C70–C72	1.7	1.1	1.7	0.5	0.8	0.5	1.8	1.3	1.9	2.5	4.3	3.4	5.9	8.2	7.2	8.2	12.7	15.5	
Thyroid	C73	0.0	0.0	0.1	0.7	3.1	4.9	5.8	7.2	11.2	16.2	15.2	18.1	19.5	19.7	18.4	17.4	16.5	14.7	
Malignant lymphoma	C81–C85, C96	0.2	0.5	0.5	2.6	0.9	3.1	1.2	2.2	3.9	5.6	8.7	14.0	15.4	20.9	29.9	32.6	40.9	46.2	
Multiple myeloma	C88, C90	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	1.4	1.0	3.5	5.1	6.9	9.2	9.7	18.3	16.8	
All leukaemias	C91–C95	2.2	2.3	1.3	1.1	1.6	1.2	3.6	1.8	2.3	4.7	4.4	6.6	8.8	10.0	10.9	16.6	17.7	19.5	




Figure 1. Trends of age-standardized cancer incidence rates for five major sites and specific sites for each sex (standard population: world population).




Figure 2. Trends of age-standardized cancer incidence rates for five major sites and specific sites for each sex (standard population: 1985 Japanese model population).

on the website (only available in Japanese, <http://ganjoho.jp/professional/statistics/monita.html>).

**Acknowledgements**

The survey on cancer incidence in Japan was conducted with contributions from the 30 registries: Hokkaido, Aomori, Iwate, Miyagi, Yamagata, Ibaraki, Tochigi, Gunma, Chiba, Kanagawa, Niigata, Toyama, Ishikawa, Fukui, Gifu, Aichi, Shiga, Kyoto, Tottori, Okayama, Hiroshima, Yamaguchi, Tokushima, Kagawa, Ehime, Kochi, Nagasaki, Kumamoto, Kagoshima and Okinawa.

**Funding**

The study was supported by the 3rd-term Comprehensive Ten-year Strategy for Cancer Control.

**Conflict of interest statement**

None declared.

**References**

1. Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2000: estimates based on data from 11 population-based cancer registries. *Jpn J Clin Oncol.* 2006;36:668–75.



2. Marugame T, Matsuda T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. *Jpn J Clin Oncol* 2007;37:884–91.
3. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. *Jpn J Clin Oncol* 2008;38:641–8.
4. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. *Jpn J Clin Oncol* 2009;39:850–8.
5. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2004: based on data from 14 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Jpn J Clin Oncol* 2010; July 20 (Epub ahead of print).
6. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1988: estimates based on data from ten population-based Cancer Registries. *Jpn J Clin Oncol* 1994;24:299–304.
7. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence in Japan 1985–89: re-estimation based on data from eight population-based cancer registries. *Jpn J Clin Oncol* 1998;28: 54–67.
8. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence in Japan. In: Tajima K, Kuroishi T, Oshima A, editors. *Cancer Mortality and Morbidity Statistics—Japan and the World*. Tokyo: Japanese Scientific Societies Press 2004;95–130.